GeneDx reports Q3 adjusted EPS 49c, consensus 42c

Reports Q3 revenue $116.7M, consensus $104.67M. “GeneDx’s (WGS) accelerated growth reflects more than business momentum – it’s proof of the profound impact we’re making for families navigating rare disease and the broader transformation underway across healthcare,” said CEO Katherine Stueland. “The FDA’s Breakthrough Device Designation for our ExomeDx and GenomeDx tests underscores our innovative leadership in delivering faster, more accurate diagnoses when every day matters. Powered by GeneDx Infinity, we’re helping usher in a new era of proactive, personalized care that begins at birth – advancing precision medicine to improve outcomes and change lives.” “Q3 delivered volume acceleration coupled with gross margin expansion, and we’ve established a powerful scale advantage that sets the stage for profitable growth,” said Kevin Feeley, CFO. “As we capitalize on a rapidly expanding market, we’re investing to unlock sustainable, high growth with attractive margins.”